Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000730967 | SCV000858737 | uncertain significance | not provided | 2017-12-14 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485887 | SCV002776110 | uncertain significance | Alagille syndrome due to a NOTCH2 point mutation; Hajdu-Cheney syndrome | 2021-12-08 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002535184 | SCV003489145 | uncertain significance | Hajdu-Cheney syndrome | 2024-01-02 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 1156 of the NOTCH2 protein (p.Asn1156Ser). This variant is present in population databases (rs782760871, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with NOTCH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 595426). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NOTCH2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003165971 | SCV003914224 | uncertain significance | Inborn genetic diseases | 2023-03-02 | criteria provided, single submitter | clinical testing | The c.3467A>G (p.N1156S) alteration is located in exon 21 (coding exon 21) of the NOTCH2 gene. This alteration results from a A to G substitution at nucleotide position 3467, causing the asparagine (N) at amino acid position 1156 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |